The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study.
 
Wenfeng Fang
No Relationships to Disclose
 
Qiming Wang
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose
 
Yan Wang
No Relationships to Disclose
 
Lin Wu
No Relationships to Disclose
 
Haibo Zhu
No Relationships to Disclose
 
Sheng Hu
No Relationships to Disclose
 
Zhenyu Ding
No Relationships to Disclose
 
XingYa Li
No Relationships to Disclose
 
Yuping Sun
Honoraria - AstraZeneca; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Roche
Research Funding - Pfizer; Roche
 
Yongzhong Luo
No Relationships to Disclose
 
Jian Fang
No Relationships to Disclose
 
Xiujuan Qu
No Relationships to Disclose
 
Yun Fan
No Relationships to Disclose
 
Enwen Wang
No Relationships to Disclose
 
Xingjie Wang
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
 
Liuwei Tang
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
 
Yuping Shen
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
 
Junyou Ge
Employment - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.; Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
 
Li Zhang
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Akeso Biopharma; AstraZeneca; CHINA SHIYAO PHARMA; HenRui; Roche; Sichuan Biokin Pharmaceutical
Research Funding - Akeso Biopharma (Inst); AstraZeneca (Inst); BMS (Inst); Chia Tai Tianqing Pharmaceutical Group (Inst); QiLu Pharmaceutical (Inst); Sichuan Biokin Pharmaceutical, (Inst); Sichuan Kelun-Biotech Biopharmaceutical (Inst)